Resources > Immuno-oncology


The current cell therapies for immuno-oncology have set a precedent and regulatory pathway for the treatment of hematological cancers, with proven clinical success. Despite this progress, the limitations imposed by the ad hoc nature of the manufacture of existing autologous cell therapy products and the challenges in extending their therapeutic effects to solid tumor remain. Emphasis has shifted toward the development of allogeneic immune cell therapies with the aim of improving efficacy and patient accessibility.

Due to their autologous nature, the currently approved cell therapy products for immuno-oncology directly depend on the quantity and quality of the cells isolated from the patient, who have typically undergone several lines of treatment before becoming eligible for cell therapy. For this reason, the quality of the cells used to generate the therapeutic product is often compromised by the clinical history of the patient and it is often accompanied by high rates of batch failure and the generation of suboptimal products. Cellular reprogramming techniques, such as those described by Shinya Yamanaka in the discovery of induced of pluripotent stem cells, offer a route toward fully characterized and consistent starting material for immunotherapies.

Moreover, systematized cell reprogramming approaches allow the exploration and generation of alternative, or hard-to-obtain immune cell types and subtypes. Several cytotoxic cell types, such as Natural Killer cells or γδ T cells, have been shown to be particularly efficient in detecting and destroying solid tumours. While macrophages remain controversial in their role in the tumor microenvironment, their anti-cancer characteristics continue to draw interest. The incorporation of gene modification tools further empowers the development of immune cells with enhanced efficacy and safety profiles.

View all resources 

Immuno-oncology Cell Therapy

Here we discuss technologies, such as MOGRIFY® and epiMOGRIFY™, enabling the in vitro generation of immune cell types. In addition we explore some of the genetic modifications developed to enhance the power and safety of immune cell therapies. Lastly, we look at the advantages of alternative cell populations for trafficking into the TME, anti-tumor efficacy and cell persistence.

Biotech’s pursuit of next-generation CAR-T
2021   |   Pierre-Louis Joffrin
As the industry has learnt over the past decade, cell therapy is complex and still far from perfect despite the successes. Currently, approved products are expensive, which is giving healthcare providers and insurers ...
Translating Cellular Reprogramming into Efficacious and Scalable Cell Therapies for Immuno-Oncology
2021   |   Alessandra De Riva
Adoptive cell therapy has arisen as a novel treatment for B cell malignancies, however, its clinical and commercial success still presents considerable challenges in accessibility for patients and questions regarding ...
Application Note
Cell Therapy for Autoimmune Disease: Armored Tregs to the Rescue
2021   |   Raul Elgueta, Cristina del Carmen Rosello
In disease states such as autoimmune disease, chronic viral infection, and transplant rejection, the immune system responds inappropriately to self-antigens or doesn’t resolve once the pathogen has been removed. Imm...
White Paper
The progression & delivery of adoptive cellular immune therapies
2020   |   Vicki Moignard, Alessandra De Riva & Raul Elgueta
The success and progression of chimeric antigen receptor (CAR) T cells in adoptive cellular therapies for B cell malignancies can be attributed to the effective engraftment, efficient expansion, and persistence of the...
Webinar: Transforming Personalized Medicine into Off the shelf Cell Therapies
2020   |   Alessandra de Riva
The growth in commercially available and clinically viable advanced therapeutic medicinal products (ATMPs) has highlighted new challenges for the industry. Despite the promising efficacy of gene and cell therapies, th...
Application Note
Transforming Personalized Medicine into Off-the-Shelf Cell Therapies
2020   |   Alessandra de Riva
Initial progress in cell and gene therapy has seen 12 advanced therapeutic medicinal products (ATMPs) become available on the market in 2019 for a range of conditions, from monogenic diseases to
Application Note
Computational Algorithms and Large-Scale Data for CAR T Cell Therapy Resistance
2020   |   Raul Elguela, Aida Moreno-Moral and Rodrigo Santos
Chimeric antigen receptor T (CAR T) cells have become an important and novel therapy for patients with B cell malignancies, mainly due to recent advances in gene, protein, and cell engineering. However, the success of...